Resonant Molecular Signaling

Resonant Molecular Signaling (RMS) is a novel platform that addresses a broad spectrum of disorders via a new therapeutic approach of cellular signaling.

Based on decades of laboratory research, animal-model studies, and formal clinical trials conducted by Beech Tree investigators, the underlying theory of RMS is that a healthy state is marked by normal signaling within and between cells while disease is caused by disruption of this norm. In addition, this theory supports a view in which:

  • disease, especially chronic disease, reflects regulatory dysfunction caused by disharmony among, between, and within complex systems;
  • disharmony is itself a manifestation of errors in signaling induced by the causative agent(s) of disease, and often occurs at the subcellular or even sub-molecular level;
  • the role of RMS therapy is to restore homeodynamics by reversing or eliminating one or more inappropriate signals with the consequent re-establishment of normal biological communication.

Consistent with a novel platform, the mechanisms underlying these formulations are different than current pharmacological approaches to product discovery. For instance, identifying the etiological agent for initiating disease is not important. The pathophysiologic cascade of events induced by the causative agent, or agents, is the focus. The goal of RMS therapies is to interrupt pathophysiology by selective molecular intervention—thereby restoring normal regulatory function.

As evidenced by the results of formal trials, hundreds of patients have been treated with no significant adverse side effects. Other clinical observations include:

  • effects are generally quick and reproducible in large numbers of patients;
  • therapies often positively influence seemingly unrelated medical conditions;
  • RMS products can be used in conjunction with conventional medicines or as stand alone treatments;
  • no drug interactions;
  • doses are independent of age or weight of patient;
  • follow-up visits are less often than for conventional medicines;
  • delivery by sublingual drop is effective;
  • laboratory and costly tests can be avoided in some cases.

Validation of this approach is also found in the publication of peer-reviewed papers addressing the mechanism of action and clinical efficacy of Beech Tree's therapeutic agents.

Copyright Beech Tree Labs, Inc.